Minervax
4 articles about Minervax
-
Novo Nordisk’s investment arm, Novo Holdings, invested a little more than $20 million in four different companies over the course of 2018 through its REPAIR Impact Fund. That $165 million fund was established last year to support companies developing therapies to combat antimicrobial resistance.
-
Minervax Announces Positive Results From Phase I Trial In 240 Healthy Adult Women With Its Innovative Group B Streptococcal (GBS) Vaccine To Prevent Life-Threatening Infections In Newborns
1/5/2017
-
Minervax Initiates Phase I Clinical Trial With Innovative Group B Streptococcal (GBS) Vaccine To Prevent Life-Threatening Infections In Newborns
6/2/2015
-
Minervax Release: Group B Streptococcal Vaccine For The Prevention Of Life-Threatening Infections In Newborns Secures Funding To Reach Clinical Proof Of Concept
1/8/2014